藥碼
FEB10
藥名
Febuxostat 80 mg
英文商品名
Feburic 錠劑 80 mg
中文商品名
福避痛膜衣錠
螢幕名
Feburic 錠劑 80 mg
劑型
Tab
規格
Film-coated tab 80 mg
成分
藥理分類
Antigout Agents
健保碼
BC25427100
ATC碼
藥品圖片
外觀圖片
適應症
chronic management of hypeuricemia in patients with gout.
藥理
Feburic is a potent and selective xanthine oxidase inhibitor, thereby reduces the formation of xanthine and uric acid. Feburic is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
藥動學
Bioavailability: 49%, plasma protein binding: 99.2%, primarily to albumin; Metabolism: Extensive conjugation via uridine diphosphate glucuronosyltransferases (UGTs) 1A1, 1A3, 1A9, and 2B7 and oxidation via cytochrome P450 (CYP) 1A2, 2C8, and 2C9 as well as non-P450 enzymes. Oxidation leads to formation of active metabolites; Elimination half life: 5-8 hours.
禁忌症
Hypersensitivity to febuxostat or any component of the formulation; Concurrent use with azathioprine and mercaptopurine.
懷孕分類
C
Adverse events were observed in some animal reproduction studies.
哺乳分類
Excretion in breast milk unknown/use caution
副作用
Liver function abnormalities (5% to 7%), nausea, arthralgia and rash.
劑量和給藥方法
Orally, start at 40mg once daily; may be increased to 80 mg once daily if serum uric acid levels of less than 6 mg/dL are not achieved after 2 weeks. Administer with or without meals or antacids.
小兒調整劑量
-
腎功能調整劑量
Renal impairment (severe, CrCl<30 mL/min): Limit dose to 40 mg QD
肝功能調整劑量
  • Preexisting hepatic impairment :
  • Mild to moderate impairment (Child-Pugh class A or B) : No dosage adjustment necessary.
    Severe impairment (Child-Pugh class C) :
    There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use caution.

  • Hepatotoxicity during treatment :
  • - ALT or AST >3 times ULN (in the clinical context of potential liver injury [eg, fatigue, anorexia, right upper quadrant pain, dark urine, jaundice]):
    Interrupt febuxostat therapy and evaluate. Do not reinitiate febuxostat if liver injury is confirmed or no alternate etiology for liver test abnormalities is identified.
    - ALT or AST >3 times ULN and serum total bilirubin >2 times ULN without alternative etiology : Permanently discontinue.
    安定性
    Store at 20–25°C
    藥袋資訊
    臨床用途
    高尿酸血症
    主要副作用
    噁心、皮疹、關節痛、肝功能異常
    泡製方法
    儲存方式
    請置於 15-30℃ 乾燥處儲存
    注意事項
    其他說明
    藥局 C2 | 小庫 D | 藥庫 口C23
    藥品外觀
    顏色
    06
    形狀
    04
    剝痕
    Y
    標記1
    80
    標記2
    其他
    健保藥價
    12
    自費價
    15.96
    仿單
    資料庫
    健保給付規定